NCT04402723 2022-12-01
Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1 Terminated
Clinical Trials
6 trialsNCT03135028 2020-03-06
Japanese AML
Gilead Sciences
Phase 1 Terminated
NCT02954653 2019-11-21
A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia
Pfizer
Phase 1 Terminated
NCT00427414 2015-04-29
Liposomal Daunorubicin in Treating Patients With HIV-Related Kaposi's Sarcoma
AIDS Malignancy Consortium
Phase 1 Terminated
NCT00124644 2013-05-03
Combination Chemotherapy and Tipifarnib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1 Terminated
NCT01265199 2013-01-23
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)
Ascenta Therapeutics
Phase 1 Terminated